{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:37:28Z","timestamp":1793047048924,"version":"4.5.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jaut.2026.103616","type":"journal-article","created":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T10:11:26Z","timestamp":1788689486000},"page":"103616","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Profiling immune check point inhibitors \u2013 Induced arthritis: A systematic review and pooled analyses of cohort studies"],"prefix":"10.1016","volume":"164","author":[{"given":"Francesco","family":"Natalucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3358-5606","authenticated-orcid":false,"given":"Claudia","family":"Ciancarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Meric de Bellefon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Durez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulvia","family":"Ceccarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2026.103616_bib1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu. Rev. Pathol."},{"issue":"11","key":"10.1016\/j.jaut.2026.103616_bib2","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/ni.1790","article-title":"Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal","volume":"10","author":"Fife","year":"2009","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jaut.2026.103616_bib3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/978-981-15-3266-5_2","article-title":"Molecular and cellular functions of CTLA-4","volume":"1248","author":"Van Coillie","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.jaut.2026.103616_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1198365","article-title":"Current understanding of CTLA-4: from mechanism to autoimmune diseases","volume":"14","author":"Hossen","year":"2023","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.jaut.2026.103616_bib5","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2026.103616_bib6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.semcancer.2019.06.012","article-title":"Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: a review","volume":"64","author":"Khan","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.jaut.2026.103616_bib7","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jaut.2026.103616_bib8","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res."},{"issue":"12","key":"10.1016\/j.jaut.2026.103616_bib9","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1177\/09622802211047348","article-title":"Estimating the sample mean and standard deviation from order statistics and sample size in meta-analysis","volume":"30","author":"Cai","year":"2021","journal-title":"Stat. Methods Med. Res."},{"issue":"2","key":"10.1016\/j.jaut.2026.103616_bib10","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1177\/09622802221139233","article-title":"Standard error estimation in meta-analysis of studies reporting medians","volume":"32","author":"McGrath","year":"2023","journal-title":"Stat. Methods Med. Res."},{"key":"10.1016\/j.jaut.2026.103616_bib11","unstructured":"McGrath S., Zhao X., Ozturk O., Katzenschlager S., Steele R., and Benedetti A. (in press). Metamedian: an R package for meta-analyzing studies reporting medians. Res. Synth. Methods."},{"key":"10.1016\/j.jaut.2026.103616_bib12","series-title":"Meta-Analysis with R","author":"Schwarzer","year":"2015"},{"issue":"9","key":"10.1016\/j.jaut.2026.103616_bib13","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1007\/s00432-021-03610-w","article-title":"Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience","volume":"147","author":"Bhatlapenumarthi","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.jaut.2026.103616_bib14","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.autrev.2018.05.002","article-title":"Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: fasciitis with myositis syndrome as a new complication of immunotherapy","volume":"17","author":"Narv\u00e1ez","year":"2018","journal-title":"Autoimmun. Rev."},{"issue":"2","key":"10.1016\/j.jaut.2026.103616_bib15","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.0032","article-title":"Use of magnetic resonance imaging to identify immune checkpoint inhibitor-induced inflammatory arthritis","volume":"3","author":"Subedi","year":"2020","journal-title":"JAMA Netw. Open"},{"issue":"3","key":"10.1016\/j.jaut.2026.103616_bib16","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/art.40745","article-title":"Rheumatic syndromes associated with immune checkpoint inhibitors: a single-center cohort of sixty-one patients","volume":"71","author":"Richter","year":"2019","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"10.1016\/j.jaut.2026.103616_bib17","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1093\/rheumatology\/kead438","article-title":"Baseline predictors of disease severity in immune checkpoint inhibitor-induced inflammatory arthritis","volume":"63","author":"Cappelli","year":"2024","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.jaut.2026.103616_bib18","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/annrheumdis-2019-216109","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation","volume":"79","author":"Braaten","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.jaut.2026.103616_bib19","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s10067-018-4035-0","article-title":"Inflammatory tenosynovitis and enthesitis induced by immune checkpoint inhibitor treatment","volume":"37","author":"Inamo","year":"2018","journal-title":"Clin. Rheumatol."},{"issue":"5","key":"10.1016\/j.jaut.2026.103616_bib20","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/imj.15123","article-title":"Musculoskeletal immune-related adverse events with the use of checkpoint inhibitors in malignancy","volume":"52","author":"Dey","year":"2022","journal-title":"Intern. Med. J."},{"issue":"5","key":"10.1016\/j.jaut.2026.103616_bib21","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/acr2.1026","article-title":"Sonographic findings in inflammatory arthritis secondary to immune checkpoint inhibition: a case series","volume":"1","author":"Albayda","year":"2019","journal-title":"ACR Open Rheumatol."},{"issue":"3","key":"10.1016\/j.jaut.2026.103616_bib22","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.autrev.2018.01.003","article-title":"Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors","volume":"17","author":"Lidar","year":"2018","journal-title":"Autoimmun. Rev."},{"issue":"1","key":"10.1016\/j.jaut.2026.103616_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000412","article-title":"Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity","volume":"3","author":"Calabrese","year":"2017","journal-title":"RMD Open"},{"issue":"8","key":"10.1016\/j.jaut.2026.103616_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102595","article-title":"Rheumatic immune-related adverse events associated with cancer immunotherapy: a nationwide multi-center cohort","volume":"19","author":"Roberts","year":"2020","journal-title":"Autoimmun. Rev."},{"issue":"3","key":"10.1016\/j.jaut.2026.103616_bib25","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/acr.23467","article-title":"Arthritis after cancer immunotherapy: symptom duration and treatment response","volume":"71","author":"Smith","year":"2019","journal-title":"Arthritis Care Res."},{"issue":"6","key":"10.1016\/j.jaut.2026.103616_bib26","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.semarthrit.2018.10.012","article-title":"Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: a single center experience","volume":"48","author":"Mooradian","year":"2019","journal-title":"Semin. Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.jaut.2026.103616_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000714","article-title":"Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy","volume":"4","author":"Leipe","year":"2018","journal-title":"RMD Open"},{"key":"10.1016\/j.jaut.2026.103616_bib28","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9602540","article-title":"Immune toxicity with checkpoint inhibition for metastatic melanoma: case series and clinical management","volume":"2018","author":"Lomax","year":"2018","journal-title":"J. Skin Cancer"},{"issue":"2","key":"10.1016\/j.jaut.2026.103616_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002612","article-title":"Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study","volume":"8","author":"De La Fuente","year":"2022","journal-title":"RMD Open"},{"issue":"10","key":"10.1016\/j.jaut.2026.103616_bib30","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2017-211216","article-title":"Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment","volume":"76","author":"Belkhir","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2026.103616_bib31","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211006963","article-title":"Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis","volume":"13","author":"Verspohl","year":"2021","journal-title":"Ther. Adv. Musculoskelet Dis."},{"issue":"12","key":"10.1016\/j.jaut.2026.103616_bib32","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1007\/s10067-020-05162-9","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis: a novel clinical entity with striking similarities to seronegative rheumatoid arthritis","volume":"39","author":"Liu","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.jaut.2026.103616_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.888377","article-title":"Clinical patterns and Follow-Up of inflammatory arthritis and other immune-related adverse events induced by checkpoint inhibitors. A multicenter study","volume":"9","author":"G\u00f3mez-Puerta","year":"2022","journal-title":"Front. Med."},{"issue":"3","key":"10.1016\/j.jaut.2026.103616_bib34","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1136\/annrheumdis-2017-212257","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study","volume":"77","author":"Kostine","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"41","key":"10.1016\/j.jaut.2026.103616_bib35","article-title":"Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: a single-center experience","volume":"98","author":"Kaur","year":"2019","journal-title":"Medicine (Baltim.)"},{"issue":"2","key":"10.1016\/j.jaut.2026.103616_bib36","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/1756-185X.13444","article-title":"Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy","volume":"22","author":"Liew","year":"2019","journal-title":"Int. J. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.jaut.2026.103616_bib37","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.3390\/diagnostics12081961","article-title":"Imaging findings in patients with immune checkpoint inhibitor-induced arthritis","volume":"12","author":"Ponce","year":"2022","journal-title":"Diagnostics"},{"issue":"4","key":"10.1016\/j.jaut.2026.103616_bib38","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3390\/life13040877","article-title":"Rheumatic diseases development in patients treated by Anti-PD1 immune checkpoint inhibitors: a single-centre descriptive study","volume":"13","author":"Ceccarelli","year":"2023","journal-title":"Life"},{"issue":"5","key":"10.1016\/j.jaut.2026.103616_bib39","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/rheumatology\/kez361","article-title":"An MRI study of immune checkpoint inhibitor-induced musculoskeletal manifestations myofasciitis is the prominent imaging finding","volume":"59","author":"Daoussis","year":"2020","journal-title":"Rheumatology"},{"issue":"9","key":"10.1016\/j.jaut.2026.103616_bib40","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3899\/jrheum.221182","article-title":"Successful management of checkpoint inhibitor-induced arthritis with disease-modifying antirheumatic drugs during active immune checkpoint inhibition treatment","volume":"50","author":"Brynjarsdottir","year":"2023","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2026.103616_bib41","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejca.2018.09.027","article-title":"Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: a case series","volume":"105","author":"Mitchell","year":"2018","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.jaut.2026.103616_bib42","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00262-017-2069-9","article-title":"Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies","volume":"67","author":"Buder-Bakhaya","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"issue":"7","key":"10.1016\/j.jaut.2026.103616_bib43","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.annonc.2021.03.204","article-title":"Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma","volume":"32","author":"Owen","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jaut.2026.103616_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.749064","article-title":"Immune-related adverse events in PD-1 treated melanoma and impact upon anti-tumor efficacy: a real world analysis","volume":"11","author":"Bastacky","year":"2021","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.jaut.2026.103616_bib45","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002511","article-title":"Anti-RA33 antibodies are present in a subset of patients with immune checkpoint inhibitor-induced inflammatory arthritis","volume":"8","author":"Cappelli","year":"2022","journal-title":"RMD Open"},{"issue":"4","key":"10.1016\/j.jaut.2026.103616_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2021.105168","article-title":"Rheumatic and musculoskeletal disorders induced by immune checkpoint inhibitors: consequences on overall survival","volume":"88","author":"Adda","year":"2021","journal-title":"Jt. Bone Spine"},{"issue":"8","key":"10.1016\/j.jaut.2026.103616_bib47","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.27145","article-title":"Extended Follow-Up of chronic immune-related adverse events following adjuvant Anti-PD-1 therapy for high-risk resected melanoma","volume":"6","author":"Goodman","year":"2023","journal-title":"JAMA Netw. Open"},{"issue":"1","key":"10.1016\/j.jaut.2026.103616_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2022.105457","article-title":"Musculoskeletal immune-related adverse events in 927 patients treated with immune checkpoint inhibitors for solid cancer","volume":"90","author":"Melia","year":"2023","journal-title":"Jt. Bone Spine"},{"issue":"6","key":"10.1016\/j.jaut.2026.103616_bib49","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/CJI.0000000000000271","article-title":"Association between pembrolizumab-related adverse events and treatment outcome in advanced melanoma: results from the Dutch expanded access program","volume":"42","author":"Bisschop","year":"2019","journal-title":"J. Immunother."},{"issue":"18","key":"10.1016\/j.jaut.2026.103616_bib50","doi-asserted-by":"crossref","DOI":"10.1172\/JCI180076","article-title":"Mechanisms underlying sex differences in autoimmunity","volume":"134","author":"Fairweather","year":"2024","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.jaut.2026.103616_bib51","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2023.2204754","article-title":"Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)","volume":"12","author":"Daban","year":"2023","journal-title":"Oncoimmunology"},{"issue":"10","key":"10.1016\/j.jaut.2026.103616_bib52","doi-asserted-by":"crossref","first-page":"e697","DOI":"10.1016\/S2665-9913(25)00061-X","article-title":"Whole-body MRI in patients with arthralgia or inflammatory arthritis after exposure to immune checkpoint inhibitors: a single-centre prospective imaging study","volume":"7","author":"Harnden","year":"2025","journal-title":"Lancet Rheumatol."},{"issue":"8","key":"10.1016\/j.jaut.2026.103616_bib53","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1097\/RHU.0000000000001370","article-title":"Checkpoint inhibitor-associated arthritis: a systematic review of case reports and case series","volume":"27","author":"Ghosh","year":"2021","journal-title":"J. Clin. Rheumatol."},{"issue":"3","key":"10.1016\/j.jaut.2026.103616_bib54","first-page":"557","article-title":"High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population","volume":"69","author":"Manoussakis","year":"1987","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"10.1016\/j.jaut.2026.103616_bib55","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001085","article-title":"Recherche clinique en rhumatismes inflammatoires. Measuring ACPA in the general population or primary care: is it useful?","volume":"6","author":"Finckh","year":"2020","journal-title":"RMD Open"},{"issue":"2","key":"10.1016\/j.jaut.2026.103616_bib56","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/cei.13136","article-title":"Anti-nuclear antibodies in patients with breast cancer","volume":"193","author":"Nisihara","year":"2018","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"10.1016\/j.jaut.2026.103616_bib57","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cdp.2004.10.002","article-title":"Spectra of antinuclear antibodies in patients with squamous cell carcinoma of the lung and of the head and neck","volume":"29","author":"Fern\u00e1ndez Madrid","year":"2005","journal-title":"Cancer Detect. Prev."},{"issue":"3","key":"10.1016\/j.jaut.2026.103616_bib58","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1191\/0961203304lu521oa","article-title":"Clinical significance of antinuclear antibodies in malignant diseases: association with rheumatic and connective tissue paraneoplastic syndromes","volume":"13","author":"Solans-Laqu\u00e9","year":"2004","journal-title":"Lupus"},{"issue":"3","key":"10.1016\/j.jaut.2026.103616_bib59","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3390\/diagnostics14030320","article-title":"Comprehensive exploration of antinuclear antibodies (ANAs): unveiling clinical significance, associations with cancer, and the nuances of differential diagnosis in positive ANA patients","volume":"14","author":"Kraev","year":"2024","journal-title":"Diagnostics"},{"key":"10.1016\/j.jaut.2026.103616_bib60","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.imlet.2019.03.002","article-title":"Antinuclear antibodies in patients with cervical lesions and invasive cervical cancer","volume":"208","author":"Skare","year":"2019","journal-title":"Immunol. Lett."},{"issue":"3","key":"10.1016\/j.jaut.2026.103616_bib61","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jaut.2006.09.001","article-title":"Autoantibody profiling to identify individuals at risk for systemic lupus erythematosus","volume":"27","author":"Wandstrat","year":"2006","journal-title":"J. Autoimmun."},{"issue":"16","key":"10.1016\/j.jaut.2026.103616_bib62","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMoa021933","article-title":"Development of autoantibodies before the clinical onset of systemic lupus erythematosus","volume":"349","author":"Arbuckle","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2026.103616_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.610952","article-title":"Efficacy and feasibility of programmed Death-1\/Programmed death Ligand-1 blockade therapy in non-small cell lung cancer patients with high antinuclear antibody titers","volume":"11","author":"Mouri","year":"2021","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.jaut.2026.103616_bib64","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s10147-023-02445-4","article-title":"Clinical significance of antinuclear antibody as prognostic marker for first-line pembrolizumab in advanced non-small cell lung cancer","volume":"29","author":"Mouri","year":"2024","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.jaut.2026.103616_bib65","article-title":"The presence of autoantibodies is associated with improved overall survival in lung cancer patients","volume":"13","author":"Jing","year":"2023","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.jaut.2026.103616_bib66","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s10238-024-01317-z","article-title":"Antinuclear antibodies may predict the development of immune-related adverse events in asymptomatic patients treated with immune checkpoint inhibitors: results from a single-center cohort","volume":"24","author":"Ceccarelli","year":"2024","journal-title":"Clin. Exp. Med."},{"issue":"1","key":"10.1016\/j.jaut.2026.103616_bib67","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.jaut.2026.103616_bib68","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/cei\/uxae073","article-title":"Prevalence and clinical significance of anti-SSA antibody in the Chinese health screening population","volume":"218","author":"Jia","year":"2024","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jaut.2026.103616_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1716014","article-title":"Serum autoantibody profiles in cancer patients treated with immune checkpoint inhibitors: a cross-sectional study","volume":"15","author":"Chen","year":"2025","journal-title":"Front. Oncol."},{"issue":"14","key":"10.1016\/j.jaut.2026.103616_bib70","doi-asserted-by":"crossref","first-page":"7705","DOI":"10.3390\/ijms25147705","article-title":"Ro60-Roles in RNA processing, inflammation, and rheumatic autoimmune diseases","volume":"25","author":"Mahla","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.jaut.2026.103616_bib71","first-page":"114","article-title":"Sicca\/Sj\u00f6gren's syndrome triggered by PD-1\/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR)","volume":"37","author":"Ramos-Casals","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jaut.2026.103616_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2025.152773","article-title":"Two clinical subgroups of immune checkpoint inhibitor-induced inflammatory arthritis determined by latent class analysis","volume":"74","author":"Cappelli","year":"2025","journal-title":"Semin. Arthritis Rheum."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841126000946?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841126000946?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:05:21Z","timestamp":1793045121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841126000946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":72,"alternative-id":["S0896841126000946"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2026.103616","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Profiling immune check point inhibitors \u2013 Induced arthritis: A systematic review and pooled analyses of cohort studies","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2026.103616","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103616"}}